Table 5.

Treatment-Related Adverse Events

	Lenvatinib Group (n=27)		Lenvatinib Plus Camrelizumab Group (n=21)
	All Grade	Grade3/4	All Grade	Grade3/4
Hand-foot skin reaction	2 (7.41%)	1 (3.70%)	5 (23.81%)	1 (4.76%)
Hypertension	6 (22.22%)	4 (14.81%)	7 (33.33%)	3 (14.29%)
RECCP	0	0	3 (14.29%)	0
Weight loss	0	0	0	0
Decreased appetite	1 (3.70%)	0	0	0
Nausea	4 (14.81%)	0	0	0
Diarrhea	2 (7.41%)	1 (3.70%)	2 (9.52%)	0
Alopecia	2 (7.41%)	0	1 (4.76%)	0
Weakness	1 (3.70%)	0	0	0
Rash	2 (7.41%)	0	0	0
Hemorrhage	2 (7.41%)	0	0	0
Hoarseness	0	0	1 (4.76%)	0
Mucositis	1 (3.70%)	0	0	0
Pain	3 (11.11%)	0	1 (4.76%)	0
Myelosuppression
Decreased white blood cell	1 (3.70%)	1 (3.70%)	1 (4.76%)	0
Decreased red blood cell	1 (3.70%)	0	0	0
Decreased platelet count	1 (3.70%)	0	2 (9.52%)	1 (4.76%)
Abnormal hepatic function
Increased blood bilirubin	4 (14.81%)	0	1 (4.76%)	0
Increased alanine aminotransferase	6 (22.22%)	0	2 (9.52%)	0
Increased aspartate aminotransferase	7 (25.93%)	0	5 (23.81%)	0
Abnormal renal function
Proteinuria	4 (14.81%)	0	3 (14.29%)	0
Increased creatinine	0	0	0	0
Increased urea nitrogen	0	0	0	0
Abnormal cardiac function
Increased creatine kinase	0	0	4 (19.05%)	0
Increased creatine kinase isoenzyme	0	0	3 (14.29%)	0
Hypothyroidism	0	0	2 (9.52%)	0

Abbreviation: RECCP, reactive cutaneous capillary endothelial proliferation.